.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Rivastigmine tartrate - Generic Drug Details

« Back to Dashboard
Rivastigmine tartrate is the generic ingredient in two branded drugs marketed by Novartis, Watson Labs, Dr Reddys Labs Inc, Sun Pharm Inds, Macleods Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Orchid Hlthcare, and Alembic Pharms Ltd, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-two drug master file entries for rivastigmine tartrate. Fifteen suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: rivastigmine tartrate

Tradenames:2
Patents:0
Applicants:9
NDAs:10
Drug Master File Entries: see list32
Suppliers / Packaging: see list15
Therapeutic Class:Antidementia Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices

Pharmacology for Ingredient: rivastigmine tartrate

Tentative approvals for RIVASTIGMINE TARTRATE

Applicant Application No. Form Dosage
<disabled><disabled>SOLUTION; ORAL2MG/ML

Clinical Trials for: rivastigmine tartrate

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL204572-001Mar 25, 2016RXNo
Dr Reddys Labs Inc
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL077130-002Oct 31, 2007RXNo
Sun Pharm Inds
RIVASTIGMINE TARTRATE
rivastigmine tartrate
CAPSULE;ORAL077131-002Oct 22, 2007RXNo
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: rivastigmine tartrate

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-003Apr 21, 20004,948,807<disabled>
Novartis
EXELON
rivastigmine tartrate
CAPSULE;ORAL020823-006Apr 21, 20005,602,176<disabled>
Novartis
EXELON
rivastigmine tartrate
SOLUTION;ORAL021025-001Apr 21, 20004,948,807<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc